ATLANTA, GA – – (NewMediaWire – March 14, 2024) – – A shareholder class action lawsuit has been filed against Anavex Life Sciences Corp. (“Anavex” or the “Company”) (NASDAQ: AVXL). The lawsuit alleges that Defendants made materially false and misleading statements and/or failed to disclose material adverse information regarding the Company’s primary product, blarcamesine, its research program, the resulting data, and the methods used to analyze its studies.

If you bought Anavex shares between February 1, 2022 and January 1, 2024, and suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey Holzer, Esq. at cholzer@holzerlaw.com, by toll-free telephone at (888)-508-6832 or, you may visit the firm’s website at www.holzerlaw.com/case/anavex/ to learn more.

The deadline to ask the court to be appointed lead plaintiff in the case is May 13, 2024.